Ignite Creation Date:
2024-05-06 @ 10:40 AM
Last Modification Date:
2024-10-26 @ 12:33 PM
Study NCT ID:
NCT03320265
Status:
TERMINATED
Last Update Posted:
2018-07-06
First Post:
2017-10-10
Brief Title:
Phosphorylcholine PC-mAb Effects in Subjects With Elevated Lipoprotein a
Sponsor:
Athera Biotechnologies AB
Organization:
Athera Biotechnologies AB
Study Overview
Official Title:
Double-blind Randomised Placebo-controlled Multicentre Phase IIa Study to Investigate the Effect of PC-mAb on Arterial Inflammation in Subjects With Elevated Lipoprotein a
Status:
TERMINATED
Status Verified Date:
2018-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Terminated
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Inflammation and abnormal amount of lipids in the blood are key factors for the development and progression of atherosclerosis thickening of the artery wall and cardiovascular disease Lipoprotein a is a pro-inflammatory plasma lipoprotein that is believed to be a risk factor for cardiovascular diseases Vascular inflammation generates a range of effects including endothelial dysfunction and migration of white blood cells into the vessel wall which results in increased risk of cardiovascular events
This study is designed to assess the effects of multiple monthly intravenous infusions with the fully human antibody called PC-mAb in subjects with elevated lipoprotein a
This study is designed to assess the effects of multiple monthly intravenous infusions with the fully human antibody called PC-mAb in subjects with elevated lipoprotein a
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None